Renowned Researcher Ethan Russo, MD, Has Joined Canurta as Senior Medical Advisor & Licenses IP

Canurta is pleased to announce that Ethan Russo, MD, the preeminent global medical Cannabis expert, has joined the executive team as Senior Medical Advisor and will provide an exclusive license to related IP through his company CReDO Science, LLC. 

“Our partnership with Dr. Ethan Russo became a no-brainer once we realized we had a shared focus on bringing hemp polyphenols to people and pets in need of better treatment outcomes for inflammation, starting with more than 200 million Americans that would benefit from natural and safe solutions to manage chronic pain and disease. Combining our strengths across research capabilities and innovative technology will accelerate our path to market and ability to serve a variety of pressing health needs,” said Akeem Gardner, Founder and CEO of Canurta.

Dr. Ethan Russo, Founder and CEO of CReDO Science, brings over 25 years of clinical cannabis research experience and psychopharmacology insights to Canurta. He is a board-certified neurologist and author of 60+ peer-reviewed journal articles and 7 books. He is well known for 16 years of ground-breaking work as Senior Medical Advisor and Consultant to GW Pharmaceuticals, now Jazz Pharmaceuticals. He served as the medical monitor and study physician to GW Pharmaceuticals for more than 20 Phase I-III clinical trials of Sativex® and Epidiolex®.

As Senior Medical Advisor, Ethan will provide Canurta with essential formulation and clinical research design expertise, which is foundational to both natural product and drug development. Together, Dr. Ethan Russo and Canurta will combine innovation and novel IP from multiple sources to build science-based natural products across lucrative categories, and botanical drugs that can target multiple inflammatory-related disease indications with a combined market of over $400B by 2027. 2022 will see Dr. Russo increase his time with the company as Canurta expands research capacity and its commercial efforts.

"Inflammation is the common culprit at the root of many human health problems, particularly in relation to injuries, and is a constant unwanted companion in our aging populations. Unfortunately, the most common remedy, non-steroidal anti-inflammatory drugs (NSAIDs), are notorious for their side-effects,” said Dr. Russo. He continues, “I’m pleased to be able to outlicense our IP to Canurta and to work together on groundbreaking product development and research of these potent anti-inflammatory compounds.”

Canurta and CReDO Science agree that better health solutions often come from botanicals — compounds from plants that can address inflammation without unwanted side-effects. Hemp contains numerous non-intoxicating compounds with potent anti-inflammatory benefits that lack these dangers by working through novel pathways that provide the promise of safer treatment for a wide variety of conditions.

About Canurta

Canurta designs all-natural and innovative ingredients from hemp polyphenols to successfully support prevention and recovery from inflammation. 

Our mission is to solve the world’s biggest health challenge: preventing and managing chronic disease safely. We target inflammation because it is the root cause of disease. And we build natural solutions backed by science to rival synthetic anti-inflammatory ingredients that aren’t safe for daily or long-term support.

The hemp plant contains over 400 bioactive compounds, including unique polyphenols that only Canurta can identify, optimize and capture. While different polyphenols are found across the plant world, hemp polyphenols are valuable due to their ability to eliminate inflammation at the source through dual inhibition of pro-inflammatory pathways.  

About CReDO Science

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.